Visual prognosis in patients with Behçet's disease receiving colchicine, systemic corticosteroid or cyclosporin.
We reviewed retrospectively the charts of 36 patients (72 eyes) with Behçet's disease. The visual acuities in 21 patients receiving colchicine (group A) gradually decreased with time. The visual acuities in 9 patients receiving colchicine and systemic corticosteroid (group B) gradually decreased after the onset of the disease and were significantly worse than those in group A 10 and 15 years after onset. The visual acuities in 6 patients receiving colchicine and cyclosporin (group C) gradually decreased, and their visual acuity scores were similar to those in group A.
Hayasaka
S
S
Department of Ophthalmology, Shimane Medical University, Izumo, Japan.
Kawamoto
K
K
Noda
S
S
Kodama
T
T
D000328:Adult; D001528:Behcet Syndrome / Q000188:drug therapy* / Q000503:physiopathology; D003078:Colchicine / Q000627:therapeutic use*; D016572:Cyclosporine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011239:Prednisolone / Q000627:therapeutic use*; D011379:Prognosis; D012189:Retrospective Studies; D014792:Visual Acuity
D016572:Cyclosporine; D011239:Prednisolone; D003078:Colchicine